Results 181 to 184 of about 5,762,549 (184)

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib

Cancer
Hans J. Gelderblom, Silvia Stacchiotti, Chia-Chi Lin   +2 more
exaly  

2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial

Annals of Oncology
S. Bauer, V.A. Bhadri, H. Gelderblom, S. Stacchiotti, A.J. Wagner, M. van de Sande, N.M. Bernthal, A. Lopez Pousa, A.R. Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, C. Tait, F. Zarins, N. Zeringo, B. Harrow, M.G. Sharma, M.L. Sherman, J-Y. Blay, W.D. Tap   +19 more
openaire   +1 more source

LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

Annals of Oncology
H. Gelderblom, V.A. Bhadri, S. Stacchiotti, S. Bauer, A.J. Wagner, M. van de Sande, N.M. Bernthal, A. Lopez Pousa, A.R. Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, C. Tait, A. Saunders, B. Harrow, M.G. Sharma, R. Ruiz-Soto, M.L. Sherman, J-Y. Blay, W.D. Tap   +19 more
openaire   +1 more source

P14 A Mixed-Methods Analysis to Define Minimum Clinically Importance Differences (MCIDs) in Range of Motion, Physical Function, and Worst Stiffness in Patients With Tenosynovial Giant Cell Tumor (TGCT)

Value in Health
H Gelhorn, K Cutts, T Fikre, Y Han, C Tait, N Zeringo, A Saunders, B Harrow   +7 more
openaire   +1 more source